ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EGRX Eagle Pharmaceuticals Inc

4.40
0.21 (5.01%)
After Hours
Last Updated: 22:53:43
Delayed by 15 minutes
Share Name Share Symbol Market Type
Eagle Pharmaceuticals Inc NASDAQ:EGRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.21 5.01% 4.40 4.40 4.65 4.64 4.18 4.18 99,757 22:53:43

Statement of Changes in Beneficial Ownership (4)

11/08/2017 9:41pm

Edgar (US Regulatory)


FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Braunstein Douglas L
2. Issuer Name and Ticker or Trading Symbol

EAGLE PHARMACEUTICALS, INC. [ EGRX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O HUDSON EXECUTIVE CAPITAL LP, 1185 AVENUE OF THE AMERICAS, 32ND FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)

8/9/2017
(Street)

NEW YORK, NY 10036
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   8/9/2017     P    3610   A $48.0581   (1) 954210   I   See Footnote   (2)
Common Stock   8/9/2017     P    15206   A $49.2081   (3) 969416   I   See Footnote   (2)
Common Stock   8/9/2017     P    1584   A $50.0874   (4) 971000   I   See Footnote   (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $47.67 to $48.665, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (3), and (4) to this Form 4.
(2)  These securities are held for the account of certain private investment funds (the "HEC Funds") for which Hudson Executive Capital LP, a Delaware limited partnership ("HEC"), acts as investment adviser. The Reporting Person controls the general partner of HEC and indirectly controls the general partner of the HEC Funds. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in them.
(3)  The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $48.73 to $49.58, inclusive.
(4)  The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $49.815 to $50.39, inclusive.

Remarks:
Exhibit List - Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Braunstein Douglas L
C/O HUDSON EXECUTIVE CAPITAL LP
1185 AVENUE OF THE AMERICAS, 32ND FLOOR
NEW YORK, NY 10036
X



Signatures
/s/ Michael D. Pinnisi, Attorney-in-Fact 8/11/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1 Year Eagle Pharmaceuticals Chart

1 Year Eagle Pharmaceuticals Chart

1 Month Eagle Pharmaceuticals Chart

1 Month Eagle Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock